ANALYSIS OF TREATMENT WITH VEMURAFENIB AND DABRAFENIB IN PATIENTS WITH METASTASIC MELANOMA IN A TERTIARY HOSPITAL

C. ROMERO DELGADO¹, M. SUAREZ GONZÁLEZ², G. CALZADO GOMEZ¹, N. ROMAN GONZALEZ², M. BULLEJOS MOLINA¹, J. NAZCO CASARIEGO¹

¹Hospital Universitario de Canarias, Pharmacy, San Cristóbal de La Laguna, Spain, ²Hospital Universitario Nuestra Señora de Candelaria, Pharmacy, Santa Cruz de Tenerife, Spain

BACKGROUND
In recent years new drugs have been approved for metastatic melanoma. The BRAF gene is the most common mutation in cutaneous melanomas and is present in 50% of melanomas. Vemurafenib and dabrafenib are used for the treatment of adult patients with unresectable or metastatic melanoma with BRAF V600 mutation positive.

PURPOSE
Analyze the use of targeted therapies anti B-RAF, vemurafenib or dabrafenib, combined or not with the MEK inhibitor trametinib or cobimetinib in a tertiary hospital in patients diagnosed with metastatic melanoma.

MATERIAL AND METHODS
Retrospective observational study including all patients treated with vemurafenib or dabrafenib associated or not with trametinib or cobimetinib from May 2014 to April 2016.

RESULTS
6 patients, 50% male, were evaluated with an average age of 63 years (84-46). SAP software was used for medical history, nursing and dispensations record.
1 received vemurafenib alone, 3 patients received vemurafenib associated with cobimetinib, and the other 2 received trametinib with dabrafenib.
One of the patients with dabrafenib and trametinib (2 cycles, ECOG: 2), and the patient who received vemurafenib alone (3 cycles, not reflected ECOG) are exitus.

CONCLUSIONES
It seems that the number and location of metastases, the value of LDH, ECOG 0, and the combination of drugs antiBRAF with the MEK inhibitor determines survival and tolerance to the drug, but it will take further follow-up to see the evolution of patients.

References and/or Acknowledgements